JNJ 10-K Analysis: Three Clocks Running Down on the Dividend King

Johnson & Johnson, the $94 billion healthcare company spanning pharmaceuticals and medical devices, reported $26.8 billion in net income for FY 2025 — a 90.5% surge that made it one of healthcare's most impressive earnings prints. But strip away one accounting entry — a $7.0 billion talc litigation reserve reversal — and the story inverts.

Normalized earnings grew just 5.5%. Free cash flow was flat at $19.7 billion. And the company borrowed $9.2 billion to simultaneously acquire a neuroscience platform, surge buybacks 145%, and return 93% of its free cash flow to shareholders. Below-the-line items — not operating performance — drove 73% of the pretax income increase. Operating income improved just 27% of the total, consistent with 6% revenue growth and stable margins. Three of the last three fiscal years have been dominated by one-time items: the Kenvue separation gain in FY 2023, a $5.1 billion talc charge in FY 2024, and the $7.0 billion reversal in FY 2025. Any EPS trend line is a function of endpoint selection, not underlying business performance.

At $208, the stock's normalized PE is 23.4x — not the 18.9x the headline suggests. That is 24% more expensive than GAAP investors believe. Three clocks are running on this Dividend King, and the 10-K filed February 11, 2026 reveals exactly when each one starts to bite.

The Phantom Earnings Engine

Johnson & Johnson's headline EPS of $11.03 massively overstates underlying earning power. The 90.5% net income surge that dominated headlines is almost entirely an accounting artifact — and the 10-K makes this visible for anyone willing to decompose it.

The filing discloses approximately $7.0 billion in talc litigation reserve reversals that flowed directly to pretax income. FY 2024 had carried a $5.1 billion talc charge moving in the opposite direction, creating a $12.1 billion two-year swing in the same line item. Layer in the absence of $2.05 billion in acquired in-process research and development charges (Yellow Jersey, V-Wave, Laminar acquisitions in FY 2024) and $307 million in restructuring costs, and the normalized pretax income is $26.2 billion — not $32.6 billion. After applying the 17.7% effective tax rate, normalized net income is $21.6 billion and normalized EPS is $8.87.

The distortion extends beyond one year. Over five years, JNJ's EPS compounded at 14.9% annually — but FCF per share grew just 1.4% over the same period. The entire EPS trajectory is driven by one-time items (Kenvue gain, talc charge/reversal swings) and buyback-driven share count reduction, not operating cash flow improvement.

This matters because the permanent component of the GAAP-versus-adjusted gap is growing. JNJ's serial M&A strategy — $48.8 billion in goodwill and $50.4 billion in other intangibles, together representing 49.8% of total assets — creates approximately $4.4 billion per year in intangible amortization. That is roughly $1.49 per share in permanent after-tax GAAP drag. As acquisitions continue at higher debt costs, the amortization base grows and the GAAP-normalized wedge widens. JNJ will structurally appear "cheap" on adjusted metrics and "expensive" on normalized GAAP for years.

"Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk."

That confident tone sits alongside a 93% capital return ratio, $28.2 billion in net debt, and a rising cost of debt — a disconnect between management tone and financial trajectory. Among peers, Merck's net income grew 6.6% in FY 2025 on genuine operating improvement. AbbVie's fell 1.3% during its Humira transition. Johnson & Johnson's 90.5% surge is the largest distortion in the peer group by a factor of 14.

Johnson & Johnson's normalized earnings per share of $8.87 — after stripping a $7.0 billion talc reserve reversal — puts the stock at 23.4x earnings, 24% more expensive than its headline PE suggests.

The Borrow-to-Return Machine

Johnson & Johnson has quietly shifted from conservative capital allocation to a leveraged return strategy — and the 10-K maps the trajectory in detail. Total debt surged 63% in two years, from $29.4 billion at the end of FY 2023 to $47.9 billion at FY 2025. Net debt rose even faster: 275%, from $7.5 billion to $28.2 billion. Over the same period, free cash flow was essentially flat — $18.2 billion to $19.7 billion, a cumulative increase of just 8%.

The filing makes clear where the borrowed money went. In fiscal Q1 2025, JNJ issued $9.2 billion in senior unsecured notes to fund the IntraCellular Therapies acquisition ($14.5 billion) and "general corporate purposes" — a phrase that encompasses buyback funding and general treasury needs:

"In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes."

Those new notes carry coupons of 4.50-4.80%, with maturities stretching from 2027 to 2055. JNJ's existing debt includes notes at 0.55%, 0.95%, 1.15%, and 1.30%. The new borrowing costs are 3-4x the old rates. Interest expense rose 28.6% year-over-year ($755 million to $971 million), with only a partial-year impact from the new issuance. As roughly $5.2 billion in low-rate notes mature through 2027 and refinance at current rates, the interest cost base rises structurally — estimated FY 2026 interest expense approaches $1.1 billion.

Meanwhile, the company returned $18.3 billion to shareholders: $12.4 billion in dividends plus $5.95 billion in buybacks — a 145% increase in buybacks alone. That $18.3 billion consumed 93% of free cash flow. The dividend is comfortably covered at 63% of FCF, but the combined payout only works alongside continued borrowing. Working capital deterioration added $3.2 billion in cash drag (up from $1.5 billion the prior year), with accounts receivable growing 15.7% on just 6.0% revenue growth — expanding days sales outstanding from 61 to 67 days.

Merck also surged buybacks by 289% in FY 2025, but MRK has a 16.2% five-year FCF compound annual growth rate to support the aggression. AbbVie's 3.55x net-debt-to-EBITDA ratio shows where post-cliff leverage eventually lands. JNJ's current 0.85x is trending toward ABBV territory — the question is whether it arrives there by choice or by circumstance.

Johnson & Johnson's total debt surged 63% in two years to $47.9 billion while free cash flow remained flat at $19.7 billion, funding a 145% buyback increase through $9.2 billion in new borrowing at rates 3-4x its existing debt costs.

Patent Clock and the Double Cliff

STELARA biosimilar competition is the most visible clock, and the 10-K quantifies the geography of erosion for the first time:

"The negative impact of the STELARA sales decline, due to biosimilar competition, was approximately 6.2%, 7.6% and 4.4% on worldwide, U.S. and international operational sales, respectively."

The U.S. impact of -7.6% is 73% more severe than the international -4.4% — an erosion pattern that reveals front-loaded domestic revenue loss at JNJ's highest-margin geography. This is not random: U.S. biosimilar adoption is faster and the pricing concessions are steeper. International markets typically follow with a lag, meaning global erosion has not yet peaked.

The filing explicitly attributes margin compression to the mix shift: "Unfavorable product mix driven by the decline of STELARA sales and unfavorable transactional currency in the Innovative Medicine business, and tariffs, unfavorable transactional currency and macroeconomic factors in the MedTech business." Gross margin is declining at a 1.5 percentage point quarterly trend — structural, not temporary.

The pipeline is replacing revenue but not profitability. New products introduced within the past five years account for approximately 25% of FY 2025 sales — roughly $23.5 billion — demonstrating strong pipeline productivity. CAPLYTA contributed +1.2% to Innovative Medicine operational sales growth on a partial-year basis. But underlying R&D spending actually declined 3.4% after stripping FY 2024's $2.05 billion in acquired IPR&D charges. In a year of 6% revenue growth, R&D intensity is falling — not the profile of a company accelerating innovation to replace a patent cliff.

The second clock — OPSUMIT generic entry in 2026 — creates potential overlap with continued STELARA erosion. OPSUMIT revenue is not separately disclosed, making the precise quantum unquantifiable from the 10-K. But the risk is structural: if OPSUMIT generic penetration accelerates in parallel with continued STELARA erosion, the revenue drag compounds from a single cliff to a double cliff. The effective tax rate trajectory adds a third pressure vector — rising from 11.5% in FY 2023 to 17.7% in FY 2025, with Pillar Two legislation flagged as upside risk. Each 1 percentage point increase reduces normalized after-tax earnings by approximately $262 million.

Merck faces a more existential cliff — Keytruda represents 48.8% of pharma revenue — but MRK has been converting growth to cash far more effectively, with a 16.2% five-year FCF CAGR versus JNJ's -0.5%. AbbVie successfully navigated the Humira cliff, rebuilding to 8.6% revenue growth and a +1.7 percentage point gross margin improvement. JNJ's cliff is smaller in absolute terms but coincides with leverage escalation — unlike peers whose transitions came with stronger free cash flow support.

Johnson & Johnson's STELARA biosimilar erosion hit -7.6% in the United States — 73% more severe than the -4.4% international impact — indicating front-loaded domestic revenue loss at the company's highest-margin geography.

The Separation Arithmetic

Orthopaedics grew just 1.1% in FY 2025 — a fraction of the 6.1% growth across MedTech overall. At $9.3 billion, the franchise represents 27.5% of segment revenue but contributes disproportionately less to growth, dragging blended performance. JNJ's planned separation, announced in October 2025 with a targeted 18-24 month timeline, removes the anchor.

The math of what remains is straightforward. Stripping the $9.3 billion Orthopaedics franchise leaves a residual MedTech segment of approximately $24.5 billion growing at roughly 8% — a growth rate that approaches the premium device peer group. If that residual commands Abbott-like multiples (ABT trades at 33.6x earnings), the separated MedTech could be worth significantly more per dollar of revenue than it receives embedded in JNJ's conglomerate structure.

The approximately $117 billion gap — 23% of market cap — represents the premium the market assigns for JNJ's dual pharma-device model. Separation only unlocks value if the pharma piece sustains multiples above MRK's 14.4x AND the device piece independently commands ABT-like premiums. In other words, the market would need to pay separately for the same diversification benefit it currently receives bundled. The filing itself is candid about the uncertainty:

"The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the planned separation."

The balance sheet bears the scars of this transformation. Tangible book value has deteriorated from -$2.0 billion in FY 2023 to -$17.6 billion in FY 2025 — an 8.8x worsening driven by $48.8 billion in goodwill and $50.4 billion in intangibles accumulated through serial M&A. This is structural, not operational: each acquisition adds permanent intangible overhang. The IntraCellular deal ($14.5 billion, closed April 2025) alone added $2.8 billion in goodwill through Q3, building a third therapeutic pillar in neuroscience alongside oncology and immunology. CAPLYTA contributed +1.2% to Innovative Medicine operational growth on just nine months — roughly $684 million.

The transformation thesis — from diversified healthcare conglomerate to focused pharma plus high-growth MedTech — is intellectually compelling. But it requires execution on three simultaneous fronts: divesting Orthopaedics without value leakage, integrating IntraCellular's neuroscience platform, and managing STELARA erosion. JNJ is the only $90 billion-plus company attempting all three at once, which is either unique competitive advantage or unique execution risk.

Johnson & Johnson's Orthopaedics franchise grew just 1.1% versus 6.1% for overall MedTech, and its planned separation leaves a faster-growing $24.5 billion residual segment that could command device-peer multiples.

Three Clocks — What to Watch

The 10-K reveals three concurrent risk clocks — patent erosion, leverage trajectory, and return sustainability — and the critical insight is that they compound. As STELARA erosion drains high-margin revenue (the Patent Clock), JNJ must accelerate acquisitions to replace it, which requires borrowing at 4.5-4.8% rates (the Leverage Clock). Each acquisition at higher debt costs narrows the ROIC-to-cost-of-debt spread, while the 63-year dividend streak and buyback expectations constrain management's ability to pause capital returns and deleverage (the Return Clock). The question is not whether one clock runs out — it is which one runs out first and whether the Orthopaedics separation can reset any of them.

Five metrics will signal which scenario unfolds:

1. FY 2026 Free Cash Flow. Bull: above $20.7 billion (5%+ growth), proving underlying cash generation is accelerating. Bear: below $18.5 billion, indicating working capital deterioration and patent cliff drag are compounding.

2. Normalized EPS. Bull: above $9.60 (8%+ growth from $8.87 base), demonstrating real operating leverage. Bear: below $8.50, suggesting underlying earnings power is eroding.

3. STELARA Erosion Rate. Bull: decelerating below -4% annual drag, indicating the cliff is more manageable than feared. Bear: accelerating beyond -8%, signaling front-loaded erosion with OPSUMIT overlap.

4. Net Debt/EBITDA. Bull: below 0.9x, showing discipline. Bear: above 1.2x, approaching AbbVie-like post-cliff leverage territory ahead of schedule.

5. Days Sales Outstanding. Bull: below 63 days (recovering from 67), proving collection efficiency is improving. Bear: above 70 days, indicating revenue quality issues persisting.

At $208 per share and 23.4x normalized earnings, Johnson & Johnson is priced for roughly 5-6% annual EPS growth over five years — exactly the rate it delivered in FY 2025 on a normalized basis. The filing supports that growth rate through pipeline productivity (25% of sales from products launched in the last five years) and dual-segment diversification (both segments at 6%+ growth). But it complicates the story through rising debt costs, front-loaded patent erosion, working capital deterioration, and a $4-5 billion annual intangible amortization base that widens with each deal. At this price, there is zero margin of safety if any of the three clocks accelerates.

Johnson & Johnson trades at 23.4x normalized earnings at $208 per share, implying 5-6% annual growth for five years — exactly the rate it delivered in FY 2025, leaving zero margin of safety if any of its three risk clocks accelerates.

Frequently Asked Questions

What is Johnson & Johnson's normalized earnings per share for FY 2025?

JNJ reported GAAP EPS of $11.03 for FY 2025, but this includes a $7.0 billion talc litigation reserve reversal and other one-time items. Stripping these out — along with $307 million in restructuring charges and $205 million in acquisition-related inventory step-up costs — normalized EPS is approximately $8.87. This puts the normalized price-to-earnings ratio at 23.4x at a $208 share price, which is 24% more expensive than the headline GAAP PE of 18.9x. The 10-K filed February 11, 2026 provides the specific one-time item disclosures — including the talc reversal, restructuring, and acquisition charges — needed to calculate this adjustment.

Is JNJ's dividend safe given the 93% FCF payout ratio?

Johnson & Johnson returned $18.3 billion to shareholders in FY 2025, comprising $12.4 billion in dividends and $5.95 billion in buybacks. That consumed 93% of its $19.7 billion in free cash flow. The dividend alone represents 63% of FCF — comfortably covered by a wide margin. But the combined dividend-plus-buyback payout only works alongside $9.2 billion in new debt issuance. The 63-year consecutive dividend increase streak — the hallmark of a Dividend King — is almost certainly safe, as cutting dividends would be a last resort. The 145% buyback surge, however, is the discretionary component. If FCF doesn't grow meaningfully, the buyback program could be scaled back first. With total debt up 63% in two years, JNJ is deliberately choosing leverage over dividend conservatism.

How does JNJ's STELARA biosimilar impact compare to Humira's at ABBV?

STELARA biosimilar competition created a -6.2% drag on JNJ's worldwide operational sales in FY 2025, with the U.S. impact (-7.6%) more severe than international (-4.4%). This indicates front-loaded domestic erosion — the highest-margin geography is being hit hardest first. AbbVie's Humira faced steeper initial biosimilar erosion but has successfully rebuilt with Skyrizi and Rinvoq, growing total revenue 8.6% in FY 2025 with improving gross margins (quarterly trend of +1.7 percentage points). JNJ's pipeline offsets — DARZALEX, CARVYKTI, CAPLYTA — are replacing revenue but not margin. JNJ's gross margin is declining at a 1.5 percentage point quarterly trend while ABBV's is improving. The key structural difference: ABBV's patent cliff transition came with stronger FCF support, whereas JNJ's is accompanied by flat free cash flow and rising debt.

Why did JNJ's net income grow 90% while free cash flow was flat?

The $12.7 billion gap between net income growth (+90.5%) and FCF growth (-0.7%) is almost entirely explained by three non-cash and non-operating factors. First, a $7.0 billion talc litigation reserve reversal boosted GAAP income without generating any cash. Second, the absence of $2.05 billion in acquired IPR&D charges that depressed FY 2024 earnings inflated the year-over-year comparison. Third, working capital consumed $3.2 billion in FY 2025 versus $1.5 billion in the prior year, with accounts receivable growing 15.7% on just 6.0% revenue growth. Decomposing the pretax income increase of $15.9 billion, below-the-line items accounted for 73% ($11.5 billion swing), while operating income improved just 27% ($4.3 billion). The cash flow statement reveals the true picture: operating cash flow grew just 1.1%, from $24.3 billion to $24.5 billion.

How does JNJ's valuation compare to pharmaceutical peers?

At $208, JNJ trades at 23.4x normalized earnings, using the $8.87 EPS figure after stripping one-timers from both FY 2025 and FY 2024. Merck trades at 14.4x GAAP PE with higher ROIC (20.7% versus 18.0%) and a 16.2% five-year FCF compound annual growth rate (versus JNJ's -0.5%), despite facing its own Keytruda patent cliff. Abbott trades at 33.6x, reflecting device-sector premiums and a 5.7% FCF per share CAGR. AbbVie trades at 96.4x, though that figure is distorted by Humira transition-year accounting (negative equity of -$3.3 billion). JNJ's valuation sits between pharma-cheap (MRK) and device-premium (ABT) — consistent with its dual model but leaving limited upside. The market is either paying for JNJ's diversification or has not yet recognized the normalized cost of its earnings.

What is the Orthopaedics separation worth and how does it affect JNJ?

Orthopaedics generated $9.3 billion in revenue growing at 1.1% — the slowest-growing franchise in JNJ's portfolio and 27.5% of MedTech segment revenue. Removing it leaves a residual MedTech segment of approximately $24.5 billion growing at roughly 8%, calculated from total MedTech growth of 6.1% less the Orthopaedics drag. The separation is targeted 18-24 months from the October 2025 announcement, with $307 million in restructuring charges already recorded. The filing explicitly warns that the company "cannot predict the effect of the planned separation on the trading price" — the only forward-looking risk statement about the deal's financial impact. MedTech assets total $86.5 billion (54% of operating assets for 36% of revenue), suggesting an asset-intensive separated entity. If the residual MedTech commands Abbott-like multiples (33.6x PE), the sum-of-parts math improves versus JNJ's current conglomerate valuation.

Is JNJ's rising debt a concern given its historically conservative balance sheet?

Total debt grew 63% in two years ($29.4 billion to $47.9 billion) while free cash flow was essentially flat. Net debt surged 275% ($7.5 billion to $28.2 billion). The $9.2 billion in new senior unsecured notes for IntraCellular came at rates of 4.50-4.80%, compared to existing debt at rates as low as 0.55-2.95%. Interest expense rose 28.6% year-over-year ($755 million to $971 million) with only a partial-year impact from the new issuances. As approximately $5.2 billion in low-rate notes mature through 2027, refinancing at current rates structurally raises the interest cost base. Despite this, net debt/EBITDA remains 0.85x and interest coverage is 26.4x — well within investment-grade parameters. The concern is not solvency; it is trajectory. Each acquisition and buyback cycle at higher rates narrows the gap between return on invested capital and the cost of debt.

What would make JNJ's stock a better buy?

Three measurable triggers would invalidate the cautious thesis presented in this analysis. First, FY 2026 free cash flow exceeding $20.7 billion (5%+ growth) would prove that underlying cash generation is accelerating independent of one-time items and leverage. Second, normalized EPS exceeding $9.60 (8%+ growth from the $8.87 base) would demonstrate real operating leverage, not just accounting optics. Third, STELARA erosion decelerating below -4% annual drag would indicate the patent cliff is more manageable than the current -6.2% worldwide pace suggests. Additionally, if the Orthopaedics separation generates net proceeds used to reduce debt rather than fund additional buybacks, it would reset the leverage clock. The bull case requires at least two of these four triggers to fire simultaneously.

How much did the IntraCellular Therapies acquisition contribute to JNJ's growth?

IntraCellular Therapies, which markets CAPLYTA for schizophrenia and bipolar depression, closed on April 2, 2025 and contributed +1.2% to Innovative Medicine worldwide operational sales growth — approximately $684 million in revenue on a partial-year basis of nine months. The acquisition was funded by $9.2 billion in senior unsecured notes at 4.50-4.80% (maturities from 2027 to 2055) and added approximately $2.8 billion in goodwill through Q3 2025. The deal builds JNJ's third therapeutic pillar in neuroscience alongside its established oncology (DARZALEX, CARVYKTI) and immunology (TREMFYA) franchises, targeting schizophrenia and bipolar depression with potential expansion to major depressive disorder. Annualized, CAPLYTA likely represents roughly $900 million to $1 billion in revenue.

How does JNJ's R&D spending compare to peers and is it sufficient?

JNJ spent $14.7 billion on R&D in FY 2025, representing 15.6% of revenue — second among peers behind MRK (24.3% of revenue) but ahead of ABBV (14.9%) and ABT (6.6%). However, underlying R&D actually declined 3.4% year-over-year after stripping FY 2024's $2.05 billion in acquired IPR&D charges for Yellow Jersey, V-Wave, and Laminar. The headline -15% R&D decline overstates the reduction, but a 3.4% real decline in a year of 6% revenue growth means R&D intensity is falling. The filing reports that "new products introduced within the past five years accounted for approximately 25% of 2025 sales" — roughly $23.5 billion, demonstrating strong pipeline productivity. Whether reduced underlying R&D spending today erodes that productivity in three to five years is a key monitoring question.

What is the remaining talc litigation exposure?

The filing discloses a remaining talc litigation reserve of approximately $3.4 billion, plus $1.1 billion for opioid litigation settlements — total litigation reserves of roughly $4.5 billion. The FY 2025 results include a $7.0 billion reserve reversal (following a $5.1 billion charge in FY 2024), reflecting the resolution trajectory. The talc liability has three distinct vectors: direct consumer lawsuits, talc supplier indemnification claims following Imerys Talc America's Chapter 11 bankruptcy, and insurance disputes. Management states operating cash flows and external sources will "continue to provide sufficient resources" to fund these obligations. The $3.4 billion remaining reserve compares to $19.7 billion in annual free cash flow, suggesting manageable magnitude — but new claims or adverse rulings could trigger additional charges.

What are the key risks to JNJ's FY 2026 revenue guidance of $99.5-100.5B?

The midpoint guidance of $100 billion (+6.2% growth) faces three quantifiable headwinds. First, continued STELARA erosion — if biosimilar penetration accelerates from -6.2% to -8-10% (a typical ramp trajectory), that represents a $1.5-2.0 billion incremental drag on the $94.2 billion base. Second, OPSUMIT generic entry in 2026 creates the potential for a double cliff with two patent expirations overlapping simultaneously. Third, the effective tax rate trajectory (11.5% to 15.7% to 17.7%) threatens after-tax earnings even if revenue hits the guidance target, with each 1 percentage point increase reducing net income by approximately $262 million. On the upside, CAPLYTA full-year annualization (partial year in FY 2025 due to April close) adds roughly $300-400 million in incremental revenue, and DARZALEX continues to grow as the oncology franchise anchor. The guidance is achievable but assumes no acceleration in patent cliff erosion.

Methodology

Data Sources

This analysis draws on the following primary sources:

• Johnson & Johnson FY 2025 10-K (filed February 11, 2026) — primary filing data including all financial statements, MD&A, risk factors, and footnotes (debt, segments, commitments, goodwill). Accessed via MetricDuck filing intelligence with chunk-level section granularity. Specific section attributions provided for each quote.
• MetricDuck automated pipeline — standardized financial metrics (revenue, margins, cash flow, returns, valuation ratios) extracted from XBRL filings via MetricDuck's metrics-processor. All pipeline data tagged [PIPELINE] in the underlying research.
• Peer 10-K filings (ABBV FY 2025, MRK FY 2025, ABT FY 2025) — cross-company comparison metrics via MetricDuck research pipeline.
• Derived calculations — all normalized figures (EPS, PE, NI growth, DSO, DIO, underlying R&D, intangible amortization, tax impact) use explicit formulas documented in JSX comments throughout the article and in the source verification table of the underlying research notes. 29 derived calculations with inputs and formulas are available for independent verification.

Limitations

• Normalized EPS is an estimate. The choice of which items to strip is subjective. We removed the talc reversal, restructuring, and inventory step-up but retained intangible amortization as an ongoing cost. Others may normalize differently.
• Orthopaedics segment profitability is not disclosed. Segment-level margin estimates for the separation and sum-of-parts scenario are inferred from revenue contribution and corporate margin allocation, not disclosed segment operating income.
• OPSUMIT revenue is not separately disclosed. The "double cliff" risk assessment is qualitative — the exact revenue at risk from OPSUMIT generic entry cannot be quantified from the 10-K.
• Sum-of-parts segment earnings are estimated. JNJ does not disclose segment net income. The implied equity values in the sum-of-parts table use estimated segment earnings based on revenue-weighted allocation with margin assumptions. Actual segment profitability could differ materially.
• Peer fiscal year mismatch. JNJ's FY ends December 28 (52-week convention); all peers end December 31. Margin and growth comparisons are approximately comparable but not exact.
• Market prices are as of last pipeline update. JNJ at $208, MRK at $105, ABBV at $228, ABT at $125 — all sourced from MetricDuck pipeline snapshot data, not real-time.
• Forward projections are not forecasts. The tracking metrics and thresholds are testable claims designed for monitoring, not investment recommendations.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in JNJ, ABBV, MRK, or ABT. All derived calculations are shown with formulas for verification. Filing quotes are verbatim from the Johnson & Johnson FY 2025 10-K unless otherwise noted. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.